121 related articles for article (PubMed ID: 38769661)
21. Aldo-keto reductase 1B10 promotes development of cisplatin resistance in gastrointestinal cancer cells through down-regulating peroxisome proliferator-activated receptor-γ-dependent mechanism.
Matsunaga T; Suzuki A; Kezuka C; Okumura N; Iguchi K; Inoue I; Soda M; Endo S; El-Kabbani O; Hara A; Ikari A
Chem Biol Interact; 2016 Aug; 256():142-53. PubMed ID: 27417252
[TBL] [Abstract][Full Text] [Related]
22. Aldo-keto reductase 1B10 as a Carcinogenic but Not a Prognostic Factor in Colorectal Cancer.
Ye X; Wang T; Zhong L; Farrés J; Xia J; Zeng X; Cao D
J Cancer; 2024; 15(6):1657-1667. PubMed ID: 38370384
[TBL] [Abstract][Full Text] [Related]
23. Aldo-keto reductase 1B10 protects human colon cells from DNA damage induced by electrophilic carbonyl compounds.
Zu X; Yan R; Pan J; Zhong L; Cao Y; Ma J; Cai C; Huang D; Liu J; Chung FL; Liao DF; Cao D
Mol Carcinog; 2017 Jan; 56(1):118-129. PubMed ID: 26969882
[TBL] [Abstract][Full Text] [Related]
24. AKR1B10 as a Potential Novel Serum Biomarker for Breast Cancer: A Pilot Study.
Cao Z; Delfino K; Tiwari V; Wang X; Hannan A; Zaidi F; McClintock A; Robinson K; Zhu Y; Gao J; Cao D; Rao K
Front Oncol; 2022; 12():727505. PubMed ID: 35280770
[TBL] [Abstract][Full Text] [Related]
25. AKR1B10 inhibits the proliferation and metastasis of hepatocellular carcinoma cells by regulating the PI3K/AKT pathway.
Tian K; Deng Y; Li Z; Zhou H; Yao H
Oncol Lett; 2024 Jan; 27(1):18. PubMed ID: 38034486
[TBL] [Abstract][Full Text] [Related]
26. AKR1B10 (Aldo-keto reductase family 1 B10) promotes brain metastasis of lung cancer cells in a multi-organ microfluidic chip model.
Liu W; Song J; Du X; Zhou Y; Li Y; Li R; Lyu L; He Y; Hao J; Ben J; Wang W; Shi H; Wang Q
Acta Biomater; 2019 Jun; 91():195-208. PubMed ID: 31034948
[TBL] [Abstract][Full Text] [Related]
27. Aldo-keto reductase family 1 B10 gene silencing results in growth inhibition of colorectal cancer cells: Implication for cancer intervention.
Yan R; Zu X; Ma J; Liu Z; Adeyanju M; Cao D
Int J Cancer; 2007 Nov; 121(10):2301-6. PubMed ID: 17597105
[TBL] [Abstract][Full Text] [Related]
28. Low expression of Aldo-keto reductase 1B10 is a novel independent prognostic indicator for nasopharyngeal carcinoma.
Guo Y; Luo W; Hu Z; Li J; Li X; Cao H; Li J; Wen B; Zhang J; Cheng H; Guo W; Tan T; Luo D
Cell Biosci; 2016; 6():18. PubMed ID: 26949513
[TBL] [Abstract][Full Text] [Related]
29. Prognostic value of aldo-keto reductase family 1 member B10 (AKR1B10) in digestive system cancers: A meta-analysis.
Liu R; Zheng S; Yang CY; Yu Y; Peng S; Ge Q; Lin Q; Li Q; Shi W; Shao Y
Medicine (Baltimore); 2021 Apr; 100(14):e25454. PubMed ID: 33832153
[TBL] [Abstract][Full Text] [Related]
30. Heat shock protein 90-α mediates aldo-keto reductase 1B10 (AKR1B10) protein secretion through secretory lysosomes.
Luo D; Bu Y; Ma J; Rajput S; He Y; Cai G; Liao DF; Cao D
J Biol Chem; 2013 Dec; 288(51):36733-40. PubMed ID: 24217247
[TBL] [Abstract][Full Text] [Related]
31. Overexpression of AKR1B10 in nasopharyngeal carcinoma as a potential biomarker.
He YC; Shen Y; Cao Y; Tang FQ; Tian DF; Huang CF; Tao H; Zhou FL; Zhang B; Song L; He L; Lin LM; Lu FG; Liao DF; Cao D
Cancer Biomark; 2016; 16(1):127-35. PubMed ID: 26835713
[TBL] [Abstract][Full Text] [Related]
32. Aldo-Keto Reductase Family 1 Member B10 (AKR1B10) overexpression in tumors predicts worse overall survival in hepatocellular carcinoma.
Shi J; Chen L; Chen Y; Lu Y; Chen X; Yang Z
J Cancer; 2019; 10(20):4892-4901. PubMed ID: 31598161
[TBL] [Abstract][Full Text] [Related]
33. Fidarestat induces glycolysis of NK cells through decreasing AKR1B10 expression to inhibit hepatocellular carcinoma.
Wu T; Ke Y; Tang H; Liao C; Li J; Wang L
Mol Ther Oncolytics; 2021 Dec; 23():420-431. PubMed ID: 34853813
[TBL] [Abstract][Full Text] [Related]
34. Diagnostic and Prognostic Potential of AKR1B10 in Human Hepatocellular Carcinoma.
DiStefano JK; Davis B
Cancers (Basel); 2019 Apr; 11(4):. PubMed ID: 30959792
[TBL] [Abstract][Full Text] [Related]
35. Identification and expression analysis of the aldo-ketoreductase1-B10 gene in primary malignant liver tumours.
Heringlake S; Hofdmann M; Fiebeler A; Manns MP; Schmiegel W; Tannapfel A
J Hepatol; 2010 Feb; 52(2):220-7. PubMed ID: 20036025
[TBL] [Abstract][Full Text] [Related]
36. Up-regulated aldo-keto reductase family 1 member B10 in chronic hepatitis C: association with serum alpha-fetoprotein and hepatocellular carcinoma.
Sato S; Genda T; Hirano K; Tsuzura H; Narita Y; Kanemitsu Y; Kikuchi T; Iijima K; Wada R; Ichida T
Liver Int; 2012 Oct; 32(9):1382-90. PubMed ID: 22681639
[TBL] [Abstract][Full Text] [Related]
37. Sulindac inhibits pancreatic carcinogenesis in LSL-KrasG12D-LSL-Trp53R172H-Pdx-1-Cre mice via suppressing aldo-keto reductase family 1B10 (AKR1B10).
Li H; Yang AL; Chung YT; Zhang W; Liao J; Yang GY
Carcinogenesis; 2013 Sep; 34(9):2090-8. PubMed ID: 23689354
[TBL] [Abstract][Full Text] [Related]
38. Serum aldo-keto reductase family 1 member B10 predicts advanced liver fibrosis and fatal complications of nonalcoholic steatohepatitis.
Kanno M; Kawaguchi K; Honda M; Horii R; Takatori H; Shimakami T; Kitamura K; Arai K; Yamashita T; Sakai Y; Yamashita T; Mizukoshi E; Kaneko S
J Gastroenterol; 2019 Jun; 54(6):549-557. PubMed ID: 30707282
[TBL] [Abstract][Full Text] [Related]
39. AKR1B10 is induced by hyperglycaemia and lipopolysaccharide in patients with diabetic nephropathy.
Shaw N; Yang B; Millward A; Demaine A; Hodgkinson A
Cell Stress Chaperones; 2014 Mar; 19(2):281-7. PubMed ID: 23975544
[TBL] [Abstract][Full Text] [Related]
40. Down-regulation of aldo-keto reductase AKR1B10 gene expression by a phorbol ester via the ERK/c-Jun signaling pathway.
Nishinaka T; Miura T; Sakou M; Hidaka C; Sasaoka C; Okamura A; Okamoto A; Terada T
Chem Biol Interact; 2015 Jun; 234():274-81. PubMed ID: 25463304
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
